JSJean D. Sibonga

Jean D. Sibonga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jean D. Sibonga has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dose-Response Effects of 2-Methoxyestradiol on Estrogen Target Tissues in the Ovariectomized Rat

    by J. D. Sibonga, S. Lotinun, G. L. Evans, V. S. Pribluda, S. J. Green, R. T. Turner

    In three experiments, we evaluated the pharmacological effects of 2-methoxyestradiol (2ME2) on several estrogen target tissues. Experiment 1: we gavaged recently ovariectomized (OVX) 9.5-wk-old rats with 2ME2 at doses of 0, 0.1, 1, 4, 20, and 75 mg/kg in a 21-d dose-response study. 2ME2 reduced body weight and serum cholesterol, increased uterine weight and epithelial cell height, and inhibited longitudinal and radial bone growth compared with values in the untreated OVX rat. All doses of 2ME2 maintained cancellous bone mass at the baseline level, the lowest effective dose being 20-fold less than a uterotrophic dose. Experiment 2: in an 8-wk experiment in adult OVX rats, a nonuterotrophic dose of 2ME2 (4 mg/kg·d) suppressed body weight gain, inhibited bone formation in cancellous bone and partially prevented bone loss in the tibial metaphysis. Experiment 3: in weanling rats, ICI 182,780 did not antagonize the effect of 2ME2. We conclude that 2ME2 antagonizes the skeletal changes that follow OVX at doses that have minimal or no effects in the uterus in both young and adult rats; 2ME2 does not appear to act via estrogen receptors and is active on bone at doses well below those required for tumor suppression in mice. 2ME2, through a novel pathway, may be a useful alternative to conventional hormone replacement therapy for prevention of postmenopausal bone loss.


  • Evidence that 2-methoxyestradiol suppresses proliferation and accelerates apoptosis in normal rat growth plate chondrocytes

    by Jean D. Sibonga, Ulrike Sommer, Russell T. Turner

    Purpose. 2-Methoxyestradiol (2ME2), a metabolite of 17β-estradiol, is currently undergoing extensive clinical testing as an antitumor agent. This drug antagonizes both angiogenesis and induces apoptosis in some tumor cell lines. Growth plate alterations as well as an inhibition of longitudinal bone growth have been reported in young rats treated with a pharmacological dose of 2ME2. However, 2ME2's mechanism of action at the growth plate is unknown. To uncover the mechanism, we examined the dose-response effects of 2ME2 on growth plate chondrocytes. Methods. 2ME2 (4-, 20-, and 75 mg·kg·day) was administered orally to recently ovariectomized 10-week-old rats. The number of cells undergoing DNA synthesis was evaluated with 3H-thymidine radioautography, apoptosis-induced DNA fragmentation was detected with TUNEL assay, and longitudinal growth rates were determined with fluorochrome labeling. Results. 2ME2 reduced bone elongation (P≤0.05), suppressed chondrocyte proliferation (P≤0.05), and induced chondrocyte apoptosis (P≤0.05). Furthermore, 1-week treatment with 2ME2 did not affect the size of hypertrophic chondrocytes. Conclusion. Thus, pharmacological doses of 2ME2 utilized for tumor suppression can inhibit normal bone elongation in growing rats by reducing the number of proliferating chondrocytes in the growth plate and accelerating apoptosis in differentiated chondrocytes. This demonstration identifies another organ in which toxicity should potentially be monitored in ongoing and future clinical trials of 2ME2.


  • Effects of spaceflight and simulated weightlessness on longitudinal bone growth

    by J.D Sibonga, M Zhang, G.L Evans, K.C Westerlind, J.M Cavolina, E Morey-Holton, R.T Turner


  • Open Access

    Restoration of bone mass in the severely osteopenic senescentrat

    by J D Sibonga, M Zhang, E L Ritman, R T Turner

    Studies in humans and rats suggest that age impairs the ability to formbone. This impairment may be due to a depletion or deficit inosteoprogenitor stem cells. Such a deficit would be expected to reduce theability of the skeleton to respond to therapy designed to restore lostbone. This study evaluated whether severely osteopenic senescent rats arecapable of responding to a potent anabolic factor in bone, prostaglandin E2(PGE). Growing female Sprague Dawley rats were ovariectomized at 3 monthsand aged until the start of treatment at 23 months. Rats were treated dailywith PGE (3 mg/kg sc) or vehicle for 56 days. Tibiae were harvested forbone histomorphometry and femora were obtained for mRNA analysis of bonematrix proteins. The cancellous bone area was fivefold greater inPGE-treated rats than in vehicle-treated controls and not different fromage-matched ovary-intact rats. PGE approximately doubled the bone-formingsurface and the mineral apposition rate and increased the bone formationrate fourfold. The increased cancellous bone area in PGE-treated rats wasprimarily due to an increase in osteoblasts over osteoclasts. One hundredpercent of the endocortical surface and 72 +/- 9% of the periosteal surfaceof cortical bone was undergoing mineralization in PGE-treated rats, whereasno mineratization was evident in vehicle-treated rats. An architecturalanalysis of cancellous bone indicates that trabecular number and thicknesswere increased and separation decreased in the treated rats. Imaging bymicrocomputed tomography further revealed that with PGE treatment,trabeculae in the medial plane of the proximal tibial metaphysis were morerobust and continuous with the endocortical surface. PGE also significantlyinduced message levels for the prepro- alpha (I) subunit of type I collagen(collagen), osteonectin, and osteocalcin. In summary, bone mass can berestored to severely osteopenic senescent rats, suggesting that aging doesnot necessarily diminish the capacity of the skeleton to form bone.